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Abstract
Background: Circulating concentrations of heme oxygenase-1 (HO-1) have been recently reported to be elevated in several
chronic disorders. However, no study has ever examined the association between circulating HO-1 concentrations and type
2 diabetes mellitus (T2DM).
Methods and Findings: 581 cases with newly-diagnosed T2DM (New-T2DM) and 611 comparison controls were recruited in
this two-phase case-control study, comprising 420 cases and 429 controls collected in the first phase study and 161 cases
and 182 controls in the second phase replication study. Analyses, using both separated data and combined data from the
two-phase studies, show that plasma HO-1 concentrations were significantly increased in New-T2DM cases compared to
controls (P,0.001). Plasma HO-1 concentrations were significantly correlated with plasma glucose concentrations, HOMA-
beta and HOMA-IR (P,0.001). After adjustment for age, sex, BMI and family history of diabetes, the ORs for New-T2DM in
the highest quartile of plasma HO-1 concentrations, compared with the lowest, was 8.23 (95% CI 5.55–12.21; P for trend
,0.001). The trend remained significant after additional adjustment for fasting plasma glucose/insulin, HOMA-beta/HOMA-
IR, TC/TG, smoking, drinking and history of hypertension, and even in further stratification analysis by age, sex, BMI,
smoking, drinking and history of hypertension.
Conclusions: Elevated plasma HO-1 concentrations are associated with higher ORs for New-T2DM, which add more
knowledge regarding the important role of oxidative stress in T2DM. More consequent studies were warranted to confirm
the clinical utility of plasma HO-1, especially in diagnosis and prognosis of T2DM and its complications.
Citation: Bao W, Song F, Li X, Rong S, Yang W, et al. (2010) Plasma Heme Oxygenase-1 Concentration Is Elevated in Individuals with Type 2 Diabetes Mellitus. PLoS
ONE 5(8): e12371. doi:10.1371/journal.pone.0012371
Editor: Cuilin Zhang, National Institute of Child Health and Human Development/National Institutes of Health, United States of America
Received March 15, 2010; Accepted July 29, 2010; Published August 25, 2010
Copyright:  2010 Bao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by National Natural Science Foundation (NSFC-30872116) and partly by National Basic Research Program (973 Program,
2009CB118803-1) of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lgliu@mails.tjmu.edu.cn (LL); fhu@hsph.harvard.edu (FBH)
. These authors contributed equally to this work.
Introduction
Although the underlying mechanisms for the pathogenesis of
type 2 diabetes mellitus (T2DM) still remain to be fully
determined, growing evidence has suggested that oxidative stress,
induced by hyperglycemia, glucose fluctuations [1] and possibly by
free fatty acid (FFA) [2], contributes to the development of T2DM
and diabetic complications [3–5]. Among a panel of potential
candidate genes related to oxidative stress, heme oxygenase-1
(HO-1) has drawn much attention as an ‘‘emerging molecule’’
with potent antioxidant, anti-inflammatory, and anti-proliferative
effects [6].
HO-1, also known as heat shock protein 32 (Hsp32), is the
inducible isoform of heme oxygenase that catalyzes the NADPH-
dependent decomposition of heme to carbon monoxide (CO),
ferrous iron, and biliverdin [7]. HO-1 expression is highly
responsive to a broad spectrum of chemical and physical stress
agents, such as hydrogen peroxide, heavy metals, UVA irradia-
tion, hypoxia, hyperoxia, pro-inflammatory cytokines and heme
itself, thus it has also been regarded as a biomarker for cell stress
status [8]. Given the potential physiological importance of HO-1
in mediating cellular homeostasis, its role in T2DM has been
investigated in considerable research. It is interesting that although
high glucose exposure failed to induce the classical antioxidant
enzymes, such as superoxide dismutase, catalase and glutathione
peroxidase, in pancreatic beta cells [9], it resulted in a remarkable
rise in both HO-1 gene expression and enzyme activities in the
islets, in parallel with hyperglycemia-induced intracellular perox-
ide levels [10,11]. Another line of research examined the effects of
the duration of hyperglycemia on HO-1 gene expression in islets of
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hyperglycemia (.150 mg/dl), blood glucose concentrations con-
tinued to increase while HO-1 expressions in islets were decreased
over time [12], which is similar with the results in our previous
study in alloxan-induced diabetic mice [13]. These studies suggest
that HO-1 induction may be an early-phase event responding to
high glucose challenge in T2DM.
Recently, elevated serum or plasma HO-1 concentrations have
been observed in several chronic disorders [14–16]. In the other
hand, HO-1 expressions in several types of cells or tissues of
individuals with T2DM have been previously reported by our
group and others [17–21]. However, no study has examined
whether circulating HO-1 concentrations are related to T2DM.
Therefore, we conducted this case-control study to investigate the
association between plasma HO-1 concentrations and T2DM in
newly diagnosed cases (New-T2DM), and moreover to quantify
this association while taking into account the effect of important
confounding factors and in the context of age, sex and body mass
index (BMI) of the study subjects.
Methods
Study population
The study protocol was approved by the Medical Ethics
Committee of Tongji Medical College and performed according to
the declaration of Helsinki. Written informed consent was
obtained from all individuals. A two-phase case-control design,
including an original study and an independent replication study,
were applied in the current study to obtain a total of 581 cases with
New-T2DM and 611 comparison controls in two independent
operations.
In the first phase, we performed an original case-control study
to include 420 cases with New-T2DM and 429 controls. All cases
were recruited from patients who, for the first time, received a
diagnosis of T2DM at the outpatient clinics of Department of
Endocrinology of Tongji Hospital affiliated to Tongji Medical
College during the period of December 2004 to December 2007.
Comparison controls were drawn from an unselected group of
population that underwent for a routine health examination in the
same hospital. The enrolled controls have a similar sex and age
distribution as to the cases. All the diabetes cases met the
respective diagnostic criteria recommended by World Health
Organization in 1999 incorporating both fasting plasma glucose
(FPG) and a 2-h oral glucose tolerance test (OGTT; 75 g of
glucose) [22]. We included only individuals with New-T2DM as
cases to avoid possible confounding effects by anti-diabetic
medications. Moreover, most New-T2DM cases were at an earlier
stage of T2DM progression. For both the cases and controls, we
restricted the study subjects to only individuals who were aged
$30 years, BMI ,40 kg/m
2, no early history of diagnosed
diabetes, nor any other clinically systemic diseases, acute or
chronic inflammatory diseases, acute respiratory infection, and
cancer.
In the second phase of the present study, we recruited another
343 participants, including 161 cases and 182 controls, with a
purpose of replication of our first phase study. The replication
study was carried out about two months after we finished the
original study. These two studies shared the same diagnostic
standard and the same inclusion/exclusion criteria.
A standard questionnaire was used to collect information about
age, sex, smoking, alcohol consumption, hypertension, and family
history of diabetes in their first-degree relatives. Anthropometric
measurements included height (m), weight (kg), and blood pressure
(mmHg) using standardized techniques. Body mass index (BMI)
was calculated as weight (kg)/square of height (m
2). All subjects
underwent a complete physical examination in the morning after
an overnight fast; venous blood samples were drawn from an
antecubital vein into heparinized tubes for plasma separation.
Laboratory Measurements
Plasma levels for biochemical parameters, including fasting
plasma glucose (FPG), 2-h post-glucose load (OGTT2h), fasting
plasma insulin (FPI), total cholesterol (TC) and triglycerides (TG),
were measured as previously described [23]. Intra- and inter-assay
coefficients of variation were ,4% for all these assays.
Homeostasis model assessment of beta cell function (HOMA-
beta) and insulin resistance (HOMA-IR) were employed to assess
the status of insulin secretion and insulin action, respectively.
HOMA-beta =206FPI (mU/ml)/[FPG (mmol/L)23.5], HOMA-
IR = FPG (mmol/L) 6FPI (mU/ml)/22.5 [24].
Plasma HO-1 concentrations were determined by enzyme-
linked immunosorbent assay [14–16] using commercially available
sandwich kits (EKS-800, Stressgen Bioreagents; now Assay
Designs, Ann Arbor, MI, USA). HO-1 concentrations from the
samples were quantitated by interpolatig absorbance readings at
450 nm in a microplate reader (Synergy 2 multimode microplate
reader, Bio-Tek Instrument, Winooski, VT, USA) from a standard
curve generated with the calibrated HO-1 protein standard
provided. The intra-assay and inter-assay coefficient of variation
of the HO-1 ELISA kit has been determined to be ,10%.
Statistical Analysis
Statistical analyses were performed using SPSS for windows
software version 12.0 (SPSS Inc, Chicago, IL, USA). Descriptive
statistics were calculated for all demographic and clinical
characteristics of the study subjects. Comparisons between
diabetes cases and controls were performed by Chi-square
(categorical variables), t test (continuous variables, normal
distribution) or Mann-Whitney U test (continuous variables,
skewed distribution). Because plasma HO-1 concentrations
showed a skewed distribution, Spearman correlation coefficients
were used to describe the correlation between HO-1 and the
continuous variables of interest. After adjustment for age, sex and
body mass index (BMI), partial Spearman correlation coefficients
were calculated between HO-1 and other variables.
Multivariate logistic regression analysis was used to evaluate the
independent association of plasma HO-1 concentration with the
likelihood of New-T2DM. Hosmer-Lemeshow goodness-of-fit tests
were used to evaluate the appropriate model fit. Adjustments were
made for age and sex (Model 1); additionally made for BMI and
family history of diabetes (Model 2); additionally made for FPG
and FPI (Model 3a) and HOMA-IR and HOMA-beta (3b). For
calculation of the odds ratios (ORs) for New-T2DM, plasma HO-1
concentrations were categorized in quartiles according to the
control group: category 1, ,0.63 ng/ml; category 2, 0.63–
1.14 ng/ml, category 3, 1.14–2.06 ng/ml and category 4,
$2.06 ng/ml. Then we conducted stratified analyses by age
(,55, $55 y), sex, and overweight (BMI,24, $24 kg/m
2) [25].
Likelihood ratio test was used to examine statistical significance of
interactions between the above variables and HO-1 concentra-
tions.
We performed all above described analyses for the data
collected in the two-phase studies, both separately and with the
combined data. Due to the highly consistency on almost all study
variables and observed correlations between HO-1 and other
variables, we used combined data for the later multivariate
statistical analysis. All reported P values are 2-sided and P,0.05
were considered to be statistically significant.
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Demographic and clinical characteristics of the two-phase study
subjects are shown separately in Table 1 (Original Study) and
Table 2 (Replication Study), respectively, and then with the
combined data in Table 3 (Combined Study). In both the original
study and the replication study, the individuals with New-T2DM,
compared to controls, had higher BMI, higher prevalence of
family history of diabetes and hypertension, and higher levels of
triglyceride, total cholesterol, FPG, OGTT 2h and plasma HO-1.
When looking at the insulin sensitivity indexes, we, as expected,
observed a lower HOMA-beta but a higher HOMA-IR in
diabetes cases than that in the controls (Tables 1, 2 and 3).
Plasma HO-1 concentrations were significantly increased in
patients with New-T2DM compared with controls. In the original
study, Median (interquartile range, IQR) is 2.42 (1.39–3.90) ng/ml
vs. 1.11 (0.63–2.06) ng/ml in diabetes cases vs. controls,
respectively (P,0.001); and in the replication study, that is 2.62
(1.81–3.97) vs. 1.22 (0.61–2.06), respectively (P,0.001) (Tables 1,
2 and 3).
Table 4 shows correlations between plasma HO-1 concentra-
tions and relevant variables. Plasma HO-1 concentrations were
significantly correlated with plasma glucose concentrations,
HOMA-beta, and HOMA-IR. In the original study, Spearman
correlation coefficient (r) is 0.351 for FPG, 0.317 OGTT2h,
20.285 for HOMA-beta, and 0.192 for HOMA-IR, respectively
(all P,0.001); and in the replication study, r is 0.529 for FPG,
0.400 for OGTT2h, 20.316 for HOMA-beta, and 0.481 for
HOMA-IR, respectively (all P,0.001). In partial correlation
analysis, after adjustment for age, sex and BMI, these correlations
between plasma HO-1 concentrations and other variables above
were attenuated but they remained significant in both studies.
Moreover, when we performed the above analyses using the
combined data from the original study and replication study, the
trend is still unchanged (Table 4).
As mentioned above, most of the study variables and observed
correlations between HO-1 and other variables were highly
consistent between the original study and replication study.
Therefore we performed subsequent multivariate analyses with
combined data (Table 5 and Table 6), in attempt to strengthen the
statistical power.
Table 5 shows logistic analysis results of odds ratios (ORs) for
New-T2DM associated with the level of plasma HO-1
concentrations, categorized into the quartiles according to its
distribution in the controls. We observed increased ORs for
New-T2DM associated with higher level of the plasma HO-1
concentration – likely a dose-response trend of this association.
Participants in the highest quartile of plasma HO-1 concentra-
tions, compared with the lowest, had a significantly increased
ORs for New-T2DM (crude OR 8.11, 95% CI 5.50–11.96; P
for trend ,0.001). Adjustment for age and sex (adjusted OR
8.34, 95% CI 5.63–12.36; P for trend ,0.001; Model 1) or
further adjustment for BMI and family history of diabetes
(adjusted OR 8.23, 95% CI 5.55–12.21; P for trend ,0.001;
Model 2) did not alter the results. Additional adjustment for
FPG and FPI only moderately attenuated the association
(adjusted OR 4.89, 95% CI 2.14–11.17, P for trend ,0.001).
The OR was 5.33 (95% CI 2.29–12.43, P for trend ,0.001)
after additional adjustment for HOMA-IR and HOMA-beta,
5.35 (95% CI 2.31–12.41, P for trend ,0.001) after additional
adjustment for TC and TG and 3.99 (95% CI 1.48–10.75, P for
trend =0.004) after additional adjustment for smoking, alcohol
drinking and hypertension.
Table 6 shows the results of analyses stratified by age, sex,
overweight, smoking, alcohol drinking and hypertension for the
association between HO-1 and New-T2DM. After adjustment
for age, sex, BMI and family history of diabetes, high ORs for
New-T2DM and dose-response relationship between plasma
HO-1 concentration and increasing ORs of New-T2DM are
Table 1. Characteristics of the Newly Diagnosed Type 2 Diabetes Cases and Controls in the Original Study.
Characteristics Diabetes Cases Controls P Value
Number of Subjects 420 429
Age, years 51.12 (10.74) 51.90 (11.82) 0.310
Male, n (%) 246 (58.57) 230 (53.61) 0.146
BMI, kg/m
2 24.69 (22.90226.74) 23.94 (21.97225.85) ,0.001
Smoke, n (%) 203 (48.33) 172 (40.09) 0.016
Alcohol, n (%) 238 (56.67) 190 (44.29) ,0.001
Family History of Diabetes, n (%) 98 (23.33) 67 (15.62) 0.005
Hypertention, n (%) 172 (40.95) 137 (31.93) 0.006
TC (mmol/L) 5.29 (4.3426.34) 4.66 (4.0225.28) ,0.001
TG (mmol/L) 1.76 (1.1622.63) 1.26 (0.8621.81) ,0.001
FPG (mmol/L) 8.65 (7.30211.33) 5.20 (4.7025.84) ,0.001
FPI (mU/ml) 10.07 (6.36214.89) 10.14 (7.77212.40) 0.983
OGTT2h (mmol/L) 15.43 (13.35217.34) 8.57 (7.8629.60) ,0.001
HOMA-beta 37.17 (19.63270.93) 119.55 (80.942184.58) ,0.001
HOMA-IR 3.86 (2.5525.97) 2.31 (1.7823.06) ,0.001
HO-1 (ng/ml) 2.42 (1.3923.90) 1.11 (0.6322.06) ,0.001
Abbreviations: BMI, body mass index; TC, total cholesterol; TG, triglycerides; FPG, fasting plasma glucose; FPI, fasting plasma insulin; OGTT2h, 2-h post-glucose load;
HOMA-beta, homeostasis model assessment of beta cell function; HOMA-IR, homeostasis model assessment of insulin resistance.
Data are presented as number (percentage) for categorical data, mean (standard deviation) for parametrically distributed data or median (interquartile range) for
nonparametrically distributed data.
doi:10.1371/journal.pone.0012371.t001
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between plasma HO-1 concentration and gender difference (P
for interaction =0.021) as well as between plasma HO-1
concentration and hypertension (P for interaction =0.006);
however, the reason for such interactions remains to be
elucidated.
Discussion
The interesting phenomenon that HO-1, rather than classical
antioxidant enzymes, expression is significantly elevated in high
glucose exposed pancreatic islet cells has attracted a panel of
consequent studies including in vitro, in vivo and human studies.
Table 2. Characteristics of the Newly Diagnosed Type 2 Diabetes Cases and Controls in the Replication Study.
Characteristics Diabetes Cases Controls P Value
Number of Subjects 161 182
Age, years 50.10 (8.17) 49.79 (9.23) 0.741
Male, n (%) 93 (57.76) 98 (53.85) 0.467
BMI, kg/m
2 23.31 (21.94224.89) 22.72 (20.80224.89) 0.354
Smoke, n (%) 59 (36.65) 83 (45.60) 0.093
Alcohol, n (%) 71 (44.10) 77 (42.31) 0.738
Family History of Diabetes, n (%) 36 (22.36) 20 (10.99) 0.004
Hypertention, n (%) 47 (29.19) 47 (25.82) 0.485
TC (mmol/L) 4.03 (3.4324.82) 4.33 (3.8624.90) 0.003
TG (mmol/L) 1.35 (0.8522.00) 1.22 (0.7521.62) 0.059
FPG (mmol/L) 10.25 (8.32212.86) 4.86 (4.3025.60) ,0.001
FPI (mU/ml) 6.81 (4.50210.61) 8.33 (6.17212.23) 0.010
OGTT2h (mmol/L) 18.95 (16.53222.54) 8.26 (7.7328.82) ,0.001
HOMA-beta 20.70 (10.85237.43) 87.02 (63.312112.30) ,0.001
HOMA-IR 3.13 (2.0724.76) 1.19 (0.6622.04) ,0.001
HO-1 (ng/ml) 2.62 (1.8123.97) 1.22 (0.6122.06) ,0.001
Data are presented as number (percentage) for categorical data, mean (standard deviation) for parametrically distributed data or median (interquartile range) for
nonparametrically distributed data.
doi:10.1371/journal.pone.0012371.t002
Table 3. Characteristics of the Newly Diagnosed Type 2 Diabetes Cases and Controls in the Combined Population from both the
Original Study and Replication Study.
Characteristics Diabetes Cases Controls P Value
Number of Subjects 581 611
Age, years 50.83 (10.10) 51.27 (11.14) 0.477
Male, n (%) 339 (58.35) 328 (53.68) 0.105
BMI, kg/m
2 24.22 (22.49226.17) 23.67 (21.67225.54) ,0.001
Smoke, n (%) 262 (45.09) 255 (41.73) 0.242
Alcohol, n (%) 309 (53.18) 267 (43.70) 0.001
Family History of Diabetes, n (%) 134 (23.06) 87 (14.24) ,0.001
Hypertention, n (%) 219 (37.69) 184 (30.11) 0.006
TC (mmol/L) 4.93 (3.9626.03) 4.56 (3.9725.15) ,0.001
TG (mmol/L) 1.61 (1.0522.46) 1.25 (0.8321.78) ,0.001
FPG (mmol/L) 9.17 (7.47211.83) 5.10 (4.6025.79) ,0.001
FPI (mU/ml) 8.96 (5.86213.40) 9.24 (6.18211.98) 0.287
OGTT2h (mmol/L) 16.20 (13.71218.50) 8.44 (7.8329.45) ,0.001
HOMA-beta 32.52 (16.47262.70) 106.63 (72.682169.20) ,0.001
HOMA-IR 3.60 (2.3625.48) 2.05 (1.3622.87) ,0.001
HO-1 (ng/ml) 2.51 (1.5323.93) 1.14 (0.6222.06) ,0.001
Data are presented as number (percentage) for categorical data, mean (standard deviation) for parametrically distributed data or median (interquartile range) for
nonparametrically distributed data.
doi:10.1371/journal.pone.0012371.t003
HO-1 Is Elevated in T2DM
PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e12371However, the current study, to our knowledge, is the first direct
attempt to examine the relationship between circulating HO-1
concentrations and T2DM. Our study indicated that elevated
plasma HO-1 concentrations were associated with an increased
OR for New-T2DM, with strong dose-response trend. The
association between plasma HO-1 concentrations and New-
T2DM could not be explained by possible confounding effects
from adjusting factors including age, sex, BMI, family history of
diabetes, FPG, FPI, HOMA-beta and HOMA-IR, and it did not
differentiates by age, sex and BMI. Therefore, these observations
hold on in the analyses with the data of the first original study and
the later replication study separately, making the observed
association between plasma HO-1 concentrations and New-
T2DM more convincing.
As an inducible stress protein, HO-1 is widely accepted to be a
highly sensitive and reliable marker of oxidative stress [8,26].
Reduced defense capacity against oxidative stress was found in
cultured HO-1-deficient embryonic fibroblasts in vitro, HO-1-
deficient mice in vivo [27,28], and it was further confirmed in a
typical human case with a complete loss of exon-2 of the maternal
allele and a two-nucleotide deletion within exon3 of the paternal
allele in HO-1 gene [29]. In contrast, up-regulation of HO-1
protein may represent an attempt to minimize cellular injury [30].
The current study demonstrated that plasma HO-1 concentrations
were significantly increased in individuals with New-T2DM
compared to controls. This is in parallel with our previous study
which found predominant oxidative stress in the form of lipid
peroxidation and DNA oxidative damage in New-T2DM [23].
Similar elevated HO-1 concentrations have been recently reported
in other chronic disorders, such as chronic silicosis [14],
Parkinson’s disease [15] and hemophagocytic syndrome [16].
The sources and mechanisms of circulating HO-1 remain to be
elucidated. Schipper et al postulated that plasma HO-1 may
represent ‘‘leakage’’ of the enzyme from tissues to the plasma
compartment analogous to the presence of circulating liver
enzymes [31]. It was supported by subsequent investigations
suggesting that elevated circulating HO-1 levels may derive from
lesions of specific tissues [14,32]. Because HO-1 is highly
expressed in pancreatic islets or pancreatic beta cells [10–12],
we therefore suppose that increased levels of HO-1 in plasma may
result from ‘‘leakage’’ of injured pancreatic islets in individuals
with New-T2DM. Obviously, confirmation for this hypothesis
might be difficult in human studies; however, it could be carried
out in a type 2 diabetic animal model.
Intracellular HO-1 gene expression in patients with T2DM
seems to be complex since several relevant studies have yielded
inconsistent results. It was reported that HO-1 gene expression
was significantly increased in circulating monocytes [18] and
lymphocytes [19] while decreased in muscular samples [20] and
total leucocytes [21] in patients with T2DM. The reason for the
inconsistent HO-1 levels in various cells or tissues remains
unknown. HO-1 gene polymorphism among those studied
population might contribute in some degree [17]. Another possible
explanation might be HO-1 expression variation at different stages
of diabetes, because HO-1 has been found to be increased in early
stage of diabetes while decreased in late stage of diabetes [13].
However, it remains to be confirmed in longitudinal prospective
investigations. It is also noteworthy that the current study found an
elevation in plasma HO-1 concentration whereas our previous
case-control study in which intracellular HO-1 protein expression
in peripheral blood mononuclear cells was detected by flow
cytometry in 606 healthy controls, 65 patients with impaired
glucose regulation, and 217 patients with New-T2DM showed
decreased HO-1 expression in peripheral blood mononuclear cells
in New-T2DM [17]. This may be due to the possibility that
plasma HO-1 concentrations in New-T2DM originated from
other sources than peripheral blood mononuclear cells, which is
similar with previous report [31].
Although our study showed strong association between plasma
HO-1 and New-T2DM, it has several limitations. First, case-
control study design does not allow us to establish a temporal
relationship, so these findings should be confirmed in further
prospective cohort studies. In addition, all participants in this study
were of Chinese Han ethnicity, which minimizes the confounding
effects by ethnic background. Whether these results can be
generalized to other populations need to be studied further.
In conclusion, this study demonstrates a strong association
between plasma HO-1 concentrations and ORs for New-T2DM –
an apparent dose-response relationship that is independent of
known risk factors for T2DM. Such findings add more knowledge
regarding the important role of oxidative stress in T2DM. More
Table 4. Spearman Correlation Coefficients between Plasma
HO-1 Levels and Other Variables in the Study Subjects.
Unadjusted
Adjusted for Age,
Sex and BMI
Variables r P value r P value
Original Study
Age 20.055 0.112 / /
BMI 0.151 0.003 / /
TC 0.085 0.013 0.028 0.420
TG 0.104 0.002 0.045 0.198
FPG 0.351 ,0.001 0.226 ,0.001
FPI 0.003 0.940 0.019 0.577
OGTT2h 0.317 ,0.001 0.209 ,0.001
HOMA-beta 20.285 ,0.001 20.188 ,0.001
HOMA-IR 0.192 ,0.001 0.107 0.002
Replication Study
Age 0.255 ,0.001 / /
BMI 0.044 0.415 / /
TC 20.076 0.161 20.035 0.521
TG 0.024 0.657 0.017 0.755
FPG 0.529 ,0.001 0.311 ,0.001
FPI 0.307 ,0.001 0.269 ,0.001
OGTT2h 0.400 ,0.001 0.286 ,0.001
HOMA-beta 20.316 ,0.001 20.153 0.005
HOMA-IR 0.481 ,0.001 0.346 ,0.001
Combined Study
Age 0.026 0.362 / /
BMI 0.112 ,0.001 / /
TC 0.033 0.260 0.011 0.708
TG 0.078 0.007 0.037 0.211
FPG 0.406 ,0.001 0.258 ,0.001
FPI 0.060 0.038 0.064 0.029
OGTT2h 0.349 ,0.001 0.234 ,0.001
HOMA-beta 20.292 ,0.001 20.179 ,0.001
HOMA-IR 0.255 ,0.001 0.153 ,0.001
The analyses are based on the data from both cases and controls.
doi:10.1371/journal.pone.0012371.t004
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Quartile of Plasma HO-1 Levels
Variable 1 (Lowest) 2 3 4 (Highest) P Value for Trend
Plasma HO-1 Levels, ng/ml ,0.63 0.6321.14 1.1422.06 $2.06 /
Type 2 Diabetes Cases/Controls, n/n 43/152 57/153 130/153 351/153 /
Crude OR (95% CI) 1 1.32 (0.8422.08) 3.00 (1.9924.53) 8.11 (5.50211.96) ,0.001
Adjusted OR (95% CI), Model 1 1 1.35 (0.8622.14) 3.00 (1.9824.55) 8.34 (5.63212.36) ,0.001
Adjusted OR (95% CI), Model 2 1 1.36 (0.8622.16) 3.05 (2.0124.63) 8.23 (5.55212.21) ,0.001
Adjusted OR (95% CI), Model 3a 1 1.68 (0.6524.30) 2.87 (1.1826.99) 4.89 (2.14211.17) ,0.001
Adjusted OR (95% CI), Model 3b 1 1.64 (0.8023.38) 2.60 (1.3225.10) 5.03 (2.6729.46) ,0.001
Adjusted OR (95% CI), Model 4 1 1.63 (0.6224.28) 3.03 (1.2327.50) 5.33 (2.29212.43) ,0.001
Adjusted OR (95% CI), Model 5 1 1.61 (0.6124.20) 2.99 (1.2127.36) 5.35 (2.31212.41) ,0.001
Adjusted OR (95% CI), Model 6 1 1.11 (0.3523.49) 3.19 (1.1129.14) 3.99 (1.48210.75) 0.004
Results from multivariate Logistic regression analysis are presented using the combined data from the two-phase independent study.
Model 1, adjusted for age and sex.
Model 2, adjusted for Model 1, BMI and family history of diabetes;
Model 3a, adjusted for Model 2, FPG and FPI;
Model 3b, adjusted for Model 2, HOMA-beta and HOMA-IR.
Model 4, adjusted for Model 2, FPG, FPI, HOMA-beta and HOMA-IR.
Model 5, adjusted for Model 4, TC and TG.
Model 6, adjusted for Model 5, smoking, alcohol drinking, hypertension.
doi:10.1371/journal.pone.0012371.t005
Table 6. Odds Ratios (95% CI) of Type 2 Diabetes Prevalence in Subgroups, by Quartile of Plasma HO-1 Levels.
Quartile of Plasma HO-1 Levels
Subgroups 1 (Lowest) 2 3 4 (Highest)
P Value for
Trend
P Value for
Interaction
Age
,55 y 1 1.34 (0.7622.34) 3.32 (1.9925.53) 7.88 (4.87212.75) ,0.001 0.745
$55 y 1 1.42 (0.6423.16) 2.64 (1.2725.51) 9.17 (4.57218.39) ,0.001
Sex
Female 1 2.37 (1.1524.87) 3.12 (1.5926.12) 8.43 (4.48215.87) ,0.001 0.021
Male 1 0.88 (0.4821.63) 3.02 (1.7625.19) 8.41 (5.02214.08) ,0.001
Overweight
No 1 1.14 (0.5322.43) 2.63 (1.3225.23) 8.23 (4.20216.13) ,0.001 0.447
Yes 1 1.33 (0.7222.44) 2.59 (1.4724.56) 7.67 (4.55212.93) ,0.001
Smoking
No 1 1.32 (0.6922.53) 2.27 (1.2424.16) 6.00 (3.45210.44) ,0.001 0.243
Yes 1 1.15 (0.5422.47) 3.55 (1.8026.97) 9.36 (4.84218.11) ,0.001
Drinker
No 1 1.12 (0.5222.40) 2.58 (1.3325.02) 8.46 (4.50215.90) ,0.001 0.424
Yes 1 1.08 (0.5422.16) 3.40 (1.7826.45) 5.71 (3.14210.37) ,0.001
Hypertension
No 1 1.04 (0.5422.01) 2.64 (1.4624.79) 10.99 (6.30219.19) ,0.001 0.006
Yes 1 1.93 (0.8524.39) 3.70 (1.7627.77) 5.35 (2.63210.87) ,0.001
Results from multivariate Logistic regression analysis are presented using the combined data from the two-phase independent study.
Adjusted for age, sex, BMI and family history of diabetes.
doi:10.1371/journal.pone.0012371.t006
HO-1 Is Elevated in T2DM
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12371consequent studies were warranted to confirm the clinical utility of
plasma HO-1, especially in diagnosis and prognosis of T2DM and
its complications.
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